newsfilter
← Latest News
GlobeNewswire·

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4